Eli Lilly & Co. Upgraded to Buy by MKM Partners (LLY)
Eli Lilly & Co. (NYSE:LLY) was upgraded by analysts at MKM Partners from a “neutral” rating to a “buy” rating in a research report issued to clients and investors on Thursday, TheFlyOnTheWall.com reports. The analysts noted that the move was a valuation call.
Other equities research analysts have also recently issued reports about the stock. Analysts at Jefferies Group downgraded shares of Eli Lilly & Co. from a “hold” rating to an “underperform” rating in a research note to investors on Friday, October 11th. They now have a $40.00 price target on the stock, down previously from $49.00. Separately, analysts at Edward Jones upgraded shares of Eli Lilly & Co. from a “sell” rating to a “hold” rating in a research note to investors on Thursday, October 10th. Finally, analysts at Credit Suisse initiated coverage on shares of Eli Lilly & Co. in a research note to investors on Tuesday, October 8th. They set a “neutral” rating on the stock. Two investment analysts have rated the stock with a sell rating, eight have given a hold rating and ten have issued a buy rating to the company. Eli Lilly & Co. currently has an average rating of “Hold” and an average target price of $55.29.
Eli Lilly & Co. (NYSE:LLY) traded up 0.86% during mid-day trading on Thursday, hitting $50.745. 1,469,986 shares of the company’s stock traded hands. Eli Lilly & Co. has a one year low of $44.68 and a one year high of $58.40. The stock’s 50-day moving average is $52.91 and its 200-day moving average is $53.74. The company has a market cap of $54.815 billion and a price-to-earnings ratio of 11.30.
Eli Lilly & Co. (NYSE:LLY) last announced its earnings results on Wednesday, October 23rd. The company reported $1.11 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.04 by $0.07. The company had revenue of $5.77 billion for the quarter, compared to the consensus estimate of $5.76 billion. During the same quarter in the previous year, the company posted $0.79 earnings per share. The company’s revenue for the quarter was up 6.1% on a year-over-year basis. Analysts expect that Eli Lilly & Co. will post $4.14 EPS for the current fiscal year.
The company also recently declared a quarterly dividend, which is scheduled for Tuesday, December 10th. Stockholders of record on Friday, November 15th will be given a dividend of $0.49 per share. This represents a $1.96 dividend on an annualized basis and a yield of 3.90%. The ex-dividend date of this dividend is Wednesday, November 13th.
Eli Lilly and Company discovers, develops, manufactures, and sells products, in one business segment, pharmaceutical products.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.